



General Controls

- Prohibition against adulterated or misbranded devices
- Premarket notification 510(k) requirements
- Good Manufacturing Practices (GMPs)
- Labeling
- Registration of manufacturing facilities
- Listing of device types
- Record keeping
- Repair, replacement or refund

Medical Devices - Classification

Class II - Medium Risk

- General controls alone are insufficient
 - to assure safety and effectiveness
 - existing methods available for such assurances
- Subject to special controls
- Examples: powered wheelchairs, infusion pumps, and surgical drapes



Special Controls


- Performance standards (discretionary, voluntary national or international standard, recognized by rulemaking)
- Post-market surveillance
- Patient registries
- Development and dissemination of guidelines/guidances
- Design controls
- Recommendations and other appropriate actions
- Tracking requirements


Medical Devices - Classification

Class III – High Risk


- Insufficient information exists
 - to derive general & special controls are sufficient
 - to provide reasonable assurance of the safety and effectiveness of such devices
- Such devices are:
 - Life sustaining or life supporting
 - Substantial importance preventing impairment of human health
 - or unreasonable risk of illness or injury







The Ministry of Health (Gazette not. S.O.1468 (E)-6/10/2005) declared the following STERILE DEVICES as DRUGS Section 3 (b) (iv) 1. Cardiac Stents. 6. Bone Cements. 2. Drug Eluting Stents. 7. Heart Valves. 3. Catheters. 8. Scalp Vein Set. 4. Intra Ocular Lenses. 9. Orthopedic Implants. 5. I.V. Cannulae. 10. Int. Prosthetic replacements.



hases Clinical Trials – Drugs				
Phase	No. of Subjects	Goal		
	Pre	e - Marketing		
Phase I	20-80	Evaluate Safety, Safe dosage		
Phase II	100-300	Effectiveness, Further safety		
Phase III	1000-3000	Confirm effectiveness, Monitor side effects, compare		
	Pos	st Marketing		
Phase IV	>3000	Additional info., Risks, benefits & optimal use		


Phase	Primary Intention	Desired Outcomes
First in human Studies	Feasibility of device, "No Additional Risk" Performance in target condition Demonstration, lowest risk	Non-inferior performance over control arm No Additional risk over control arm
Pivotal Studies	Safety & efficacy of Performance in target condition	"Safe for wider human use"
Post marketing surveillance	Evaluation of Device in more defined / Difficult subgroups	Performance & safety in extended cond ⁿ , Marketing tool

Clinical Trials - Application Background and Introduction

- Protocol/ Study Number
- Study Rationale & Objectives
- Study Design
 - Overview of the Study Design
 - Flow chart of the study
 - brief description methods and procedures
 - Discussion of Study Design
- Study Population
- Subject Eligibility
 - Inclusion Criteria
 - Exclusion Criteria

Clinical Trials - Application


- Study Assessments
- Study Conduct
- Study Treatment
- Adverse Events
- Ethical considerations
- Study Monitoring and supervision
- Investigational product management
- Data Analysis
- Undertaking by the investigator





Clinical Trials - TKP Protocol/ Study Number – NA Rationale – demonstrate safety & functional efficacy TKP Objective To evaluate new prosthesis for function, extracortical bridging and ease of implantation ■ To evaluate and evolve the armamentarium To evaluate and evolve the virtual implantation

Institute	Investigators	Cases to be Accrued
Group I	Dr Manish Agarwal	50
Tata Memorial Hospital	Dr Ajay Puri	
Group II		20
AIIMS	Dr Shishir Rastogi	
Group III		30
Sanchayeti Hospital	Dr Yogesh Panchwagh	
RCC Trivandrum	Dr Subin Bhaskar	
	Dr Gopalkrishnan	
Ramaiyah Medical College	Dr Srinivas CH	
	Dr Sundaresh	
Gujrat Cancer Research	Dr Mandip Shah	
Institute		



Inclusion Criteria Patients with primary malignant bone tumors around knee Patients with non metastatic disease. Tumor amenable to resection with adequate margins Possible to retain adequate limb function after resection and reconstruction Expected ultimate function is superior Patient is undergoing appropriate adjuvant therapy Informed consent from patient or parents as appropriate

Exclusion Criteria Patients with metastatic disease Tumor not amenable to resection with adequate margins Ablative surgery function superior to limb salvage Patient not undergoing appropriate adjuvant therapy Patient unwilling in the trial with new implant Patient unwilling or unreliable to follow up.

